Revolutionary AI System Transforms Colonoscopy Procedures with Accurate Lesion Detection in Real Time!

MAGENTIQ-EYE LTD., a revolutionary technology company founded in 2014, is thrilled to announce that it has received FDA clearance via the 510(k) process for its innovative MAGENTIQ-COLO™. By increasing the Adenoma Detection Rate (ADR), this device is about to revolutionize the gastroenterology community and giving its patients a significant benefit.

With the FDA clearance following the European CE Mark and Israel AMAR approval from late 2021, the MAGENTIQ-COLO™ is on the brink of bringing this game-changing device to the US market.

Colorectal cancer (CRC) is one of the top three leading causes of cancer-related death in America, according to the National Institutes of Health (NIH). But early detection and screening for the disease can help to reduce this mortality rate.

One of the most effective means of doing so is a colonoscopy, a procedure that utilizes an endoscope equipped with a camera to traverse the length of the colon in order to search for any precancerous growths or polyps.

Despite the widespread practice of colonoscopy as a standard of care in the developed world with over 15 to 20 million procedures each year in the U.S. alone, tragically, missed polyps and undetected adenomas are still endangering many patients.

In fact, the consequences of these undetected abnormalities can result in dreaded interval cancers, accounting for 8-10% of all colorectal cancer cases – meaning that each year, over 13,500 cases could have been prevented with more effective detection.

In 2022, MAGENTIQ-COLO™ was rigorously tested by 29 endoscopy experts across 10 leading medical centers. Impressive results emerged, with the AI solution increasing ADR by 26%, translating to a 21% decrease in CRC occurrence and a 35% decrease in patient mortality – a remarkable 7% improvement in absolute values.

We are delighted to announce that MAGENTIQ-EYE has cleared FDA approval, joining a select group of companies leveraging the power of AI to offer enhanced accuracy in colonoscopies. This breakthrough will enable us to save the lives of thousands of Americans by catching potential early signs of CRC.

Our sense of accomplishment is nothing short of immense, and we are committed to pushing the boundaries of AI in gastroenterology even further. Look out for upcoming products and features from MAGENTIQ-EYE soon.

MAGENTIQ-COLO™ is making waves in the U.S. market with a local subsidiary and a dedicated network of agents, set to bring the cutting-edge technology to your doorstep. Get the competitive edge today with this must-have product!

About MAGENTIQ-EYE Ltd.

Since its founding in 2014, MAGENTIQ-EYE has revolutionized the field of colonoscopy with its groundbreaking AI-assisted solution. Receiving global accolades from the world of gastroenterology, MAGENTIQ-COLO™ is being used for dozens of procedures every day, setting the new standard of colonoscopy and saving precious lives.

Leave a Comment